Menu
← Oncology Approval Tracker
FDA DECISION ·
Talzenna + enzalutamide
talazoparib with enzalutamide · Pfizer
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer and homologous recombination repair (HRR) gene mutations identified by an FDA-authorized test.
LAMPGEN ANALYSIS
Why it matters
This PARP inhibitor combination moves into an earlier metastatic setting for patients with qualifying HRR mutations. Distinguish this population from the existing castration-resistant indication.
What research teams should watch
Build a review trail for the HRR result, prior androgen-pathway treatment and the timing of testing. Use the trial report to distinguish radiographic progression from survival outcomes.
PRIMARY RECORDS